Nearly 70% say reducing manual processes is a key priority for working with sites About Veeva Systems Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholder ...

Company Performance - Veeva Systems (VEEV) closed at $279.76, down 1.02% from the previous trading session, underperforming the S&P 500 which lost 0.08% [1] - Over the last month, VEEV shares decreased by 0.6%, outperforming the Medical sector's loss of 3.99% but lagging behind the S&P 500's gain of 1.21% [2] Upcoming Earnings - Veeva Systems is set to release its earnings report on August 27, 2025, with an expected EPS of $1.9, reflecting a 17.28% growth year-over-year [3] - The Zacks Consensus Estimate for revenue is projected at $767.61 million, indicating a 13.52% increase from the previous year [3] Full-Year Estimates - The full-year Zacks Consensus Estimates predict earnings of $7.64 per share and revenue of $3.1 billion, representing year-over-year changes of +15.76% and +12.78%, respectively [4] - Recent changes in analyst estimates for Veeva Systems may indicate shifting business trends, with positive revisions suggesting analyst optimism [4] Valuation Metrics - Veeva Systems has a Forward P/E ratio of 36.98, which is a premium compared to the industry average of 23.67 [7] - The company has a PEG ratio of 1.59, while the industry average PEG ratio is 2.66 [7] Industry Ranking - The Medical Info Systems industry, part of the Medical sector, holds a Zacks Industry Rank of 91, placing it in the top 37% of over 250 industries [8] - Strong individual industry groups, as measured by the Zacks Industry Rank, tend to outperform weaker groups by a factor of 2 to 1 [8]

Core Viewpoint - Veeva Systems (VEEV) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Business Improvement Indicators - The increase in earnings estimates and the Zacks rating upgrade for Veeva suggest an improvement in the company's underlying business, which could lead to higher stock prices [4][9]. - For the fiscal year ending January 2026, Veeva is expected to earn $7.64 per share, with a 4.1% increase in the Zacks Consensus Estimate over the past three months [7]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have averaged a +25% annual return since 1988 [6][8]. - The upgrade of Veeva to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Core Insights - Philip Morris International (PM) has seen significant growth in its e-vapor brand VEEV, with shipment volumes more than doubling year over year in Q2 2025, reaching nearly 1.5 billion equivalent units in the first half of 2025, positioning VEEV as a key growth driver alongside IQOS and ZYN [1][9] Group 1: VEEV Brand Performance - VEEV is leading the closed pod market in six European countries, including Italy and Greece, driven by a profitability-focused rollout strategy that enhances consumer loyalty and repeat purchase rates [2][9] - The recent launch of VEEV inPRIME in the Czech Republic aims to improve user experience with enhanced flavor, larger vapor clouds, and extended battery life, reinforcing VEEV's premium positioning [3][9] - Early traction for VEEV in markets outside Europe, such as Indonesia, Canada, and Colombia, indicates its global growth potential, supported by PM's multi-category infrastructure [4][5] Group 2: Competitive Landscape - Altria Group is revamping its NJOY product line to re-enter the e-vapor market but faces regulatory challenges and patent litigation that may hinder its progress [6] - Turning Point Brands reported nearly 10x year-over-year growth in white nicotine pouch sales, generating $22.3 million in revenues in Q1 2025, and raised its full-year sales guidance to $80-$95 million, reflecting strong consumer demand [7] Group 3: Financial Performance and Estimates - PM's shares have declined by 10% in the past month, contrasting with the industry's decline of 2.9% [8] - PM's forward price-to-earnings ratio stands at 20.3X, higher than the industry's average of 14.7X [10] - The Zacks Consensus Estimate indicates year-over-year earnings growth of 14% for 2025 and 12% for 2026, with current estimates for 2025 earnings at $7.49 per share [11][12]

Core Insights - Veeva Systems (VEEV) is focusing on its Vault R&D platform for long-term growth, showing strong customer expansion and product adoption in clinical, regulatory, quality, and safety domains [1][6] - The company is evolving from a software vendor to a strategic infrastructure partner in drug development, leveraging deep relationships with top pharmaceutical clients and investments in domain-specific AI [1] Group 1: Market Dynamics - The competitive landscape is shifting with the emergence of AI-native challengers that offer new approaches to trial design and data workflows, posing a challenge to Veeva [2] - Veeva's integration of AI into its R&D suite is crucial as it competes with both traditional players and specialized platforms [2][6] Group 2: Peer Analysis - Dassault Systemes (DASTY) operates Medidata, which is enhancing its capabilities with AI tools for clinical trials, addressing similar challenges as Veeva [3] - Schrodinger Inc. (SDGR) is known for its AI-driven drug discovery platform, reflecting the demand for specialized tools in life sciences, which could complement Veeva's offerings [4] Group 3: Financial Performance - Veeva's shares have increased by 35.4% year-to-date, outperforming the industry growth of 10.7% [5] - The company trades at a forward price-to-sales ratio of 14.2, above the industry average, and has a Value Score of D [8] - The Zacks Consensus Estimate for VEEV's fiscal 2026 earnings indicates a 15.8% rise from the previous year [10]

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Veeva Systems (VEEV), and suggests that while the average brokerage recommendation indicates a favorable outlook, investors should be cautious and validate these recommendations with other analytical tools like the Zacks Rank [1][5][10]. Brokerage Recommendation Summary - Veeva currently has an average brokerage recommendation (ABR) of 1.97, which is between Strong Buy and Buy, based on recommendations from 27 brokerage firms [2]. - Out of the 27 recommendations, 14 are Strong Buy and 3 are Buy, accounting for 51.9% and 11.1% of all recommendations respectively [2]. Analysis of Brokerage Recommendations - The article highlights that brokerage recommendations may not effectively guide investors towards stocks with the highest potential for price appreciation, as there is often a positive bias due to the vested interests of brokerage firms [5][6]. - Research indicates that for every "Strong Sell" recommendation, there are five "Strong Buy" recommendations, suggesting a misalignment of interests between brokerage firms and retail investors [6][7]. Zacks Rank Overview - The Zacks Rank is presented as a more reliable indicator of a stock's near-term price performance, based on earnings estimate revisions rather than brokerage recommendations [8][11]. - The Zacks Rank is distinct from the ABR, as it is a quantitative model that reflects earnings estimate revisions and is updated more frequently, providing timely predictions of future stock prices [9][12]. Current Earnings Estimates for Veeva - The Zacks Consensus Estimate for Veeva's earnings for the current year remains unchanged at $7.64, indicating steady analyst views on the company's earnings prospects [13]. - Due to the recent changes in consensus estimates and other related factors, Veeva holds a Zacks Rank of 3 (Hold), suggesting a cautious approach despite the favorable ABR [14].

Core Insights - Veeva Systems' 2025 Medtech Regulatory Affairs Benchmark reveals that 50% of respondents lack full confidence in their data completeness for global product registrations, leading to increased administrative burdens for regulatory teams [1][2] - The report highlights that only 17% of respondents rate their regulatory data quality as excellent, indicating a significant opportunity for improvement in data management and automation [2] - The survey of 130 regulatory professionals identifies heavy administrative burdens (61%), siloed processes (49%), and digital tool proficiency (35%) as major challenges hindering regulatory efficiency [5] Regulatory Operations - The lengthy timelines for submission preparation are concerning, with 80% of respondents indicating that preparing a submission for a 510(k) takes a month or longer, and 24% stating it takes more than six months [5] - Organizations are spending up to two years on each MDR submission, suggesting that reducing submission timelines could lead to faster market entry and significant cost savings [5] - Only 5% of respondents utilize a fully automated process to monitor time to market, with about 67% relying on manual processes, complicating performance insights [5] Technology Adoption - There is a growing trend towards adopting regulatory information management (RIM) systems, with 56% of organizations planning to implement such systems to enhance efficiency and compliance [5] - Nearly half of the respondents (52%) are looking to develop integrations between existing systems, and 48% are interested in automated submission tracking and reporting tools to improve data accessibility [5]

Company Performance - Veeva Systems (VEEV) stock increased by 1.83% to $291.25, outperforming the S&P 500's daily gain of 0.07% [1] - Over the past month, Veeva shares gained 2.33%, which is slightly below the Medical sector's gain of 2.39% and the S&P 500's gain of 5.71% [1] Upcoming Earnings - The upcoming earnings release is projected to show an EPS of $1.9, reflecting a 17.28% increase year-over-year [2] - Revenue is estimated at $767.61 million, indicating a 13.52% increase compared to the same quarter last year [2] Annual Estimates - For the annual period, earnings are anticipated at $7.64 per share and revenue at $3.1 billion, representing increases of 15.76% and 12.78% respectively from the previous year [3] - Recent revisions to analyst forecasts are important as they reflect short-term business trends, with positive revisions indicating a favorable business outlook [3] Zacks Rank and Valuation - Veeva Systems holds a Zacks Rank of 2 (Buy), with a Forward P/E ratio of 37.42, which is above the industry average of 31 [5] - The PEG ratio for Veeva is 1.61, compared to the Medical Info Systems industry's average PEG ratio of 3.25 [6] Industry Ranking - The Medical Info Systems industry ranks in the top 30% of all industries, with a current Zacks Industry Rank of 73 [6] - The Zacks Industry Rank indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Core Insights - Veeva Systems (VEEV) is transitioning away from Salesforce's infrastructure, aiming for full independence by September 2025, which will enhance control over product development and innovation in the life sciences sector [1][6] - The Vault platform is central to Veeva's growth, with positive client feedback indicating smoother integration and improved performance [2][6] - Veeva is investing in R&D and customer support to facilitate the transition, which may impact short-term margins but is expected to drive long-term differentiation [2][6] Industry Context - The end of the partnership with Salesforce reflects a broader industry trend towards purpose-built platforms, with Salesforce continuing to expand its healthcare offerings [3] - IQVIA remains a significant competitor in the life sciences technology space, leveraging its data assets and service offerings, although its technology is less integrated than Veeva's [4] Financial Performance - Veeva's shares have increased by 36% year-to-date, outperforming the industry growth of 8.2% [5] - The forward price-to-sales ratio for Veeva is 14.3, above the industry average, indicating a premium valuation [8] - The Zacks Consensus Estimate for Veeva's fiscal 2026 earnings suggests a 15.8% increase compared to the previous year [10]

Core Insights - A significant shift is occurring in the enterprise software landscape, particularly in the life sciences CRM market, as Veeva Systems plans to end its reliance on Salesforce's cloud infrastructure by September 2025, transitioning to its proprietary Vault platform [1][2][8] Company Strategies - Veeva is focusing on life sciences by developing vertically integrated solutions tailored to the sector's needs, while Salesforce is also pushing into life sciences with its own dedicated CRM offering [2][9] - Veeva's transition to the Vault platform will provide full control over its software stack, allowing for tailored features and optimized performance, enhancing its position as a vertically integrated player [8][12] - Salesforce benefits from a proven CRM infrastructure and is expanding its presence in life sciences through its Life Sciences Cloud, which reflects its strategic intent to grow within this high-value vertical [9][14] AI and Product Innovation - Veeva is integrating AI capabilities directly into its Vault platform, with plans to launch features like Vault CRM Bot and Voice Control by late 2025, aiming to enhance productivity and compliance [10][12] - Salesforce is advancing AI through its Agentforce platform, which reached $100 million in ARR within 90 days of launch, connecting with various tools to unify workflows [11][14] Financial Performance - Veeva's shares have gained 35.7% year-to-date, while Salesforce's stock has declined by 21.1% [3] - The Zacks Consensus Estimate for Veeva's fiscal 2026 sales implies a year-over-year growth of 12.78%, with projected earnings per share of $7.64, up 15.76% year over year [15] - For Salesforce, the fiscal 2026 sales and earnings estimates imply year-over-year growth of 8.64% and 10.78%, respectively [16] Market Positioning - Veeva is positioned as a go-to vertical platform for life sciences, with strong early adoption of its Vault CRM and expanding enterprise relationships [12][13] - Salesforce remains a strong contender with its broad platform and AI-led innovation strategy, but Veeva's focused approach and platform control provide it with a competitive edge in the life sciences CRM market [21]